公开(公告)号：EP3383866A1

公开(公告)日：2018-10-10

申请号：EP16806295.8

申请日：2016-12-01

Applicant: ViiV Healthcare UK Limited

Inventor： JOHNS, Brian Alvin ,  VELTHUISEN, Emile Johann ,  WEATHERHEAD, Jason Gordon

IPC: C07D405/14 ,  C07D217/04 ,  C07D217/06 ,  C07D217/08 ,  C07D217/24 ,  C07D401/06 ,  C07D405/04 ,  C07D413/04 ,  A61K31/472 ,  A61P31/18

CPC classification number: C07D217/04 ,  A61P31/18 ,  C07D217/06 ,  C07D217/08 ,  C07D217/24 ,  C07D401/06 ,  C07D401/12 ,  C07D405/04 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14

Abstract: Compounds of Formula (I) are disclosed and methods of treating viral infections with compositions comprising such compounds.

公开(公告)号：EP3383178A1

公开(公告)日：2018-10-10

申请号：EP16804813.0

申请日：2016-12-01

Applicant: Syngenta Participations AG

Inventor： HUETER, Ottmar, Franz ,  EDMUNDS, Andrew ,  HOPPE, Mark ,  WEGE, Philip ,  MAIENFISCH, Peter ,  TURNBULL, Michael, Drysdale

IPC: A01N43/50 ,  A01N43/82

CPC classification number: A01N43/50 ,  A01N43/82 ,  C07D233/48 ,  C07D271/07 ,  C07D413/04 ,  C07D417/04

Abstract: The present invention concerns certain cyclic derivatives of guanidine compounds and their use in protecting plants, their use to control mosquitoes, and vector control management methods or control solutions comprising such a cyclic derivative of guanidine compounds, in particular the invention relates to a substrate, to a composition, comprising a cyclic derivative of guanidine compounds for controlling mosquitoes.

公开(公告)号：EP3377476A1

公开(公告)日：2018-09-26

申请号：EP16866934.9

申请日：2016-11-15

Applicant: PTC Therapeutics, Inc.

Inventor： HWANG, Seongwoo ,  WELCH, Ellen

IPC: C07D271/06 ,  C07D413/04 ,  A61K31/4245

CPC classification number: A61K31/4245 ,  C07D271/06 ,  C07D413/04

Abstract: Novel hydrogen isotope-enriched 1,2,4-oxadiazole benzoic acid compounds, methods of their use and pharmaceutical compositions thereof are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination.

公开(公告)号：EP3371151A1

公开(公告)日：2018-09-12

申请号：EP16854005.2

申请日：2016-10-10

Applicant: Agency for Science, Technology and Research

Inventor： FOO, Klement Jihao ,  POULSEN, Anders ,  KELLER, Thomas Hugo ,  LIEW, Si Si ,  CHIA, Cheng San Brian ,  ANG, Jin Yan Melgious ,  HUANG, Chuhui

IPC: C07D215/48 ,  C07D295/182 ,  C07D471/02 ,  A61K31/4709 ,  A61K31/473 ,  A61K31/496 ,  A61K31/499 ,  A61K31/4995 ,  A61P35/00 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10

CPC classification number: A61K31/496 ,  A61K31/506 ,  A61K45/06 ,  C07D215/48 ,  C07D219/04 ,  C07D221/16 ,  C07D401/04 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  A61K2300/00

Abstract: Compounds For Inhibition Of Cancer and Epigenesis The present invention relates to quinolines and 5,6,7,8-tetrahydroacridines of the formula (I) wherein Z1, Z2, X, R1 to R8 and Y are defined as described in the specification, or a pharmaceutically acceptable form or prodrug thereof, that are inhibitors of methyl transferases such as protein lysine methyltransferases and more particularly SMYD3. The present invention also relates to the methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of disorders/conditions/diseases involving, relating to or associated with enzymes having methyl transferase activities/functions and/or via unspecified/multi-targeted mechanisms.

公开(公告)号：EP2139850B1

公开(公告)日：2018-09-12

申请号：EP08748100.8

申请日：2008-04-09

Applicant: MethylGene Inc.

Inventor： TESSIER, Pierre ,  LEIT, Silvana ,  SMIL, David ,  DÉZIEL, Robert ,  AJAMIAN, Alain ,  CHANTIGNY, Yves, Andre ,  DOMINGUEZ, Celia

IPC: C07C259/06 ,  A61K31/16 ,  A61K31/18 ,  A61K31/33 ,  C07C311/19 ,  C07C323/50 ,  C07D521/00 ,  A61P35/00

CPC classification number: C07D307/79 ,  C07C259/06 ,  C07C275/42 ,  C07C311/08 ,  C07C311/21 ,  C07C323/52 ,  C07D205/04 ,  C07D207/263 ,  C07D207/337 ,  C07D209/08 ,  C07D209/44 ,  C07D211/34 ,  C07D211/46 ,  C07D211/52 ,  C07D211/64 ,  C07D211/76 ,  C07D213/56 ,  C07D213/64 ,  C07D213/70 ,  C07D213/74 ,  C07D215/26 ,  C07D219/04 ,  C07D231/14 ,  C07D233/84 ,  C07D235/16 ,  C07D235/28 ,  C07D239/26 ,  C07D239/34 ,  C07D239/38 ,  C07D239/42 ,  C07D249/06 ,  C07D267/20 ,  C07D277/36 ,  C07D277/74 ,  C07D285/12 ,  C07D295/088 ,  C07D295/155 ,  C07D295/192 ,  C07D295/205 ,  C07D295/26 ,  C07D311/84 ,  C07D317/50 ,  C07D333/24 ,  C07D401/04 ,  C07D401/06 ,  C07D409/04 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/06 ,  C07D471/04 ,  C07D491/08 ,  C07D491/10 ,  C07D513/04

Abstract: This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of the Formula (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein groups L, M, X and Y are as defined herein.

公开(公告)号：EP3368521A1

公开(公告)日：2018-09-05

申请号：EP16784525.4

申请日：2016-10-21

Applicant: Bayer CropScience Aktiengesellschaft

Inventor： FISCHER, Rüdiger ,  HAGER, Dominik ,  HOFFMEISTER, Laura ,  KAUSCH-BUSIES, Nina ,  WILCKE, David ,  WILLOT, Matthieu ,  GÖRGENS, Ulrich ,  ILG, Kerstin ,  MOSRIN, Marc ,  PORTZ, Daniela ,  TURBERG, Andreas

IPC: C07D401/04 ,  C07D413/04 ,  C07D471/04 ,  C07D487/04 ,  C07D491/056 ,  C07D498/04 ,  C07D519/00 ,  C07D213/74 ,  C07D215/48 ,  A01N43/90 ,  A01P7/00

CPC classification number: C07D471/04 ,  A01N43/52 ,  A01N43/76 ,  A01N43/90 ,  C07D213/74 ,  C07D215/48 ,  C07D401/04 ,  C07D413/04 ,  C07D487/04 ,  C07D491/056 ,  C07D498/04 ,  C07D519/00

Abstract: The invention relates to novel compounds of formulae (I) or (Γ) (formula I, II) wherein R1, R2, R3, Aa, Ab, Ac, Ad, Ae, Q and n have the meanings indicated in the description, to the use thereof as acaricides and/or insecticides for controlling animal pests, and to methods and intermediate products for the production thereof.

公开(公告)号：EP2927229B1

公开(公告)日：2018-09-05

申请号：EP13846269.2

申请日：2013-10-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： KOIKE, Tatsuki ,  YOSHIKAWA, Masato ,  NOMURA, Izumi ,  ITO, Yoshiteru ,  KIMURA, Eiji ,  HASUI, Tomoaki ,  ANDO, Haruhi ,  FUKUDA, Hiromi ,  NISHI, Toshiya

IPC: C07D413/04 ,  A61K31/422 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/553 ,  A61P25/00 ,  A61P25/14 ,  A61P25/16 ,  A61P25/28 ,  A61P43/00 ,  C07D471/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D413/04 ,  C07D519/00

Abstract: The present invention provides a compound or a salt thereof useful for an agent for the prophylaxis or treatment of neurodegenerative disease and the like. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

公开(公告)号：EP3365338A1

公开(公告)日：2018-08-29

申请号：EP16785348.0

申请日：2016-10-21

Applicant: Laboratorios del Dr. Esteve, S.A.

Inventor： VIRGILI-BERNADO, Marina ,  ALEGRET-MOLINA, Carlos

IPC: C07D413/04 ,  A61K31/5377

CPC classification number: C07D413/04 ,  A61P29/00

Abstract: The present invention relates to substituted morpholine derivatives having pharmacological activity towards the sigma (σ) receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

公开(公告)号：EP3364967A2

公开(公告)日：2018-08-29

申请号：EP16784510.6

申请日：2016-10-21

Applicant: Vifor (International) AG

Inventor： DÜRRENBERGER, Franz ,  BUHR, Wilm ,  BURCKHARDT, Susanna ,  BURGERT, Michael ,  KALOGERAKIS, Aris ,  REIM, Stefan ,  MANOLOVA, Vania ,  BOYCE, Susan ,  YARNOLD, Christopher John ,  PENA, Paula ,  SHEPHERD, Jon ,  LECCI, Cristina ,  JARJES-PIKE, Richard ,  SCOTT, John

IPC: A61K31/4184 ,  A61K31/427 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61P3/12 ,  A61P7/06 ,  A61P25/16 ,  A61P25/28 ,  A61P31/04

CPC classification number: C07D413/14 ,  A61K31/16 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/427 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/4422 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K36/9066 ,  A61K45/06 ,  A61K2300/00 ,  A61P3/12 ,  A61P7/06 ,  A61P25/16 ,  A61P25/28 ,  C07D277/56 ,  C07D401/14 ,  C07D403/14 ,  C07D413/04 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  Y02A50/411

Abstract: The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.

公开(公告)号：EP3362445A1

公开(公告)日：2018-08-22

申请号：EP16855690.0

申请日：2016-10-11

Applicant: Chong Kun Dang Pharmaceutical Corp.

Inventor： KIM, Yuntae ,  LEE, Chang Sik ,  OH, Jung Taek ,  SONG, Hyeseung ,  CHOI, Jin ,  LEE, Jaeyoung

IPC: C07D413/04 ,  C07D271/10 ,  C07D271/06 ,  C07C211/33 ,  C07C211/35 ,  A61K31/4245 ,  A61K31/506

CPC classification number: C07D271/10 ,  A61K31/4245 ,  C07D413/04 ,  C07D413/14

Abstract: The present disclosure relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present disclosure have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.